Identification of Semaphorin3B as a Direct Target of p53  by Ochi, Kensuke et al.
Identification of Semaphorin3B as a Direct Target of p531
Kensuke Ochi* ,y, Toshiki Mori*, Yoshiaki Toyama y, Yusuke Nakamura* and Hirofumi Arakawa*
*Laboratory of Molecular Medicine and Genome Technology, Human Genome Center, Institute of Medical
Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; yDepartment of
Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582,
Japan
Abstract
A cDNA microarray analysis indicated that Semaphor-
in3B (Sema3B ), a gene whose product is involved in
axon guidance and axonal repulsion, is inducible by
p53. Introduction of exogenous p53 into a glioblastoma
cell line lacking wild-type p53 (U373MG) dramatically
induced expression of Sema3B mRNA. An electropho-
retic mobility shift assay and a reporter assay confirmed
that a potential p53 binding site present in the promoter
region had p53-dependent transcriptional activity. Ex-
pression of endogenous Sema3B was induced in
response to genotoxic stresses caused by adriamycin
treatment or UV irradiation in a p53-dependent manner.
Ectopic expression of Sema3B in p53-defective cells
reduced the number of colonies in colony formation
assays. These results suggest that Sema3B might play
some role in regulating cell growth as a mediator of p53
tumor-suppressor activity.
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Introduction
The tumor-suppressing activity of p53 protein involves
elimination of cells that might otherwise become malignant
as a result of severe DNA damage or critical cellular stress,
through induction of cell cycle arrest and apoptosis [1–3].
The p53 protein initiates these processes by binding to a
specific DNA sequence (p53 binding site, p53BS) present in
target genes, inducing transcription of molecules that carry
out the required antitumorigenic functions [4].
We and others have demonstrated that p53 takes part in
many physiological roles by transactivating dozens of target
genes such as p53AIP1 [5 ] in p53-mediated apoptosis, p21/
Waf1 [6 ] in p53-mediated cell cycle arrest, and p53R2 [7 ] in
repair of damaged DNA. In view of the fact that more than 100
potential p53BS are likely to be present in the human genome
[8], we assume that many p53 target genes have not yet
been identified. To fully understand the entire spectrum of
p53 functions including its tumor-suppressive activity, it will
be essential to identify all the genes that are targets of this
transcription factor. We recently reported several novel p53
target genes using a yeast enhancer trap system [9–12] or a
differential display method [5,7,13–15]. To expand the
collection of p53 targets further, we have been applying a
third approach that exploits cDNA microarray technology.
In neurons, both genetic and epigenetic factors are
involved in physiologic and pathophysiologic states [16].
The semaphorin family of proteins is a major agent for axonal
guidance, and the axon- repulsive effects of semaphorins
have been documented in vitro and in vivo [17]. All sem-
aphorins share a conserved, 500-amino-acid ‘‘Sema’’
domain at their amino terminals, and possess variable
regions at their carboxyl ends. More than 20 semaphorins
have been identified so far (Semaphorin Nomenclature
Committee, 1999) and are classified into eight groups on
the basis of domain organization within the primary structure
and the species of origin [18]. Vertebrate semaphorins are
categorized into five groups, classes 3 through 7; classes 4,
5, and 6 possess transmembrane segments and class 7 is
characterized by a GPI anchor motif. The Semaphorin3B
(Sema3B) gene encodes a member of class 3, a group of
secreted proteins that repulse axonal extension [19]. In the
spinal cord, Sema3B is expressed in the floor plate of the
midline and does not repel commissural axons that have not
yet crossed the floor plate. However, once the commissural
axons cross the floor plate, Sema3B inhibits their extension.
Targeted inhibition of neurophilin -2, a receptor for Sema3B,
leads to defects of midline guidance in mice. Thus, Sema3B
appears to be a critical factor in formation of the mammalian
neural network [19]. We show evidence here that Sema3B is
a direct transcriptional target of p53, and that it might be
involved in p53-dependent suppression of cell growth.
Materials and Methods
Cell Lines
Human cancer cell lines U373MG (glioblastoma), H1299
( lung carcinoma), and MCF7 (breast cancer ) were pur-
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chased from the American Type Culture Collection (ATCC,
Manassas, VA). T98G (glioblastoma) was obtained from the
Japanese Collection of Research Bioresources (JCRB,
Tokyo, Japan). All cells were cultured under conditions
recommended by their respective depositors.
Detection of Genes Induced by p53
Adenoviruses containing p53 cDNA (Ad-p53 ) or  -
galactosidase cDNA (Ad-LacZ ) under control of the human
cytomegalovirus promoter were generated as described
previously [20]. U373MG cells, which lack wild - type p53,
were infected with Ad-p53 or Ad-LacZ at a multiplicity of
infection (MOI) of 80. Cells were collected 0, 6, 12, 24, and
48 hours later, and total RNA was extracted with TRIzol
reagent (Life Technologies, Rockville, MD). Poly(A) RNA
was purified from each total RNA using an mRNA purification
kit (Amersham, Piscataway, NJ). Each poly(A)+ RNA was
then amplified using Ampliscribe T7 Transcription Kits
(Epicentre Technologies, Madison, WI).
Genes induced by exogenous p53 were identified by
hybridizing the RNA to a cDNA microarray. Preparation of
probes, hybridization procedures, and scanning were per-
formed as described previously [21]. The fluorescent
intensities of Cy5 (Ad-p53 ) and Cy3 (Ad-LacZ ) for each
target spot were adjusted so that the mean Cy5/Cy3 ratio of
52 housekeeping genes for each slide became equal. One
induced gene, Sema3B, was selected from the microarray
for further investigation.
Northern Blotting
One microgram of each poly(A)+ RNA was separated on
1% agarose gels containing 1 4-morpholinepropane-
sulfonic acid and 2% formaldehyde, and transferred onto
nylon membranes. The membranes were hybridized with
random-primed, 32P- labeled Sema3B or actin cDNA,
washed with 0.1 SSC, 0.1% SDS at 658C, and exposed
for autoradiography at 808C.
Electrophoretic Mobility Shift Assay (EMSA)
The EMSA was performed as described previously [7 ]
using oligonucleotides corresponding to a putative p53
binding sequence present in the promoter of Sema3B (50 -
TCA CTT GCA TGC CCA GAG ACA TGT CT-30 for the
sense strand and 50 -AGA CAT GTC TCT GGG CAT GCA
AGT GA-30 for the antisense strand).
Luciferase Assay
One or two copies of oligonucleotides 50 -CGCGTT-
CACTTGCATGCCCAGAGA CATGTCTC-30 (sense) and
50 -TCGAGAGACATGTCTCTGGGCATGCAAGTGA A-30
(antisense) were annealed, ligated into pGL3 promoter
vector (Promega, Madison, WI), and designated p53BS1
or p53BS2. One or two copies of 50 -TCACTTTCATTCC-
CAGAGACATGTCTTC-30 (sense) and 50 -AGACATGTC-
TCTGGGAATGAAAGTGAAA-30 (antisense) were also
annealed, ligated into pGL3 promoter vector, and desig-
nated p53BS1.mt or p53BS2.mt. An additional reporter
plasmid was constructed by cloning into pGL3 Basic vector
(Promega) an 880-bp genomic sequence corresponding to
part of the promoter region, using PCR primers, 50 -
AAAACGCGTTCAAGCTCAAATGCAGAGGC-30 and 50 -
TTTCTCGAG CCACAATCACAGACACACCC-30. A clone
containing a C-to-T substitution at the fourth nucleotide in
the p53BS was generated using a QuickChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA). Lucife-
rase assays were performed as described previously [15].
Colony Formation Assay
The entire coding sequence of Sema3B cDNA, with or
without a FLAG tag at the 30 -end, was amplified by PCR
using KOD-plus-PCR Polymerase (Toyobo, Osaka, Japan)
and inserted into pcDNA3.1( + ) vector ( Invitrogen, Carlsbad,
CA). As a control, the entire coding sequence of Sema3B
cDNA was inserted into pcDNA3.1( ) vector ( Invitrogen).
Plasmidmixtures were preincubated for 30minutes with 25 l
of FuGENE reagent (Roche, Indianapolis, IN). Seven micro-
gams of each Sema3B expression vector, with or without a
FLAG tag, and control vector were transfected into approx-
imately 1104 cells of H1299 or 5104 cells of T98G and
U373MG. The transfected cells were cultured in G418-
containing culture media (0.6 g/ml for U373 and 0.8 g/ml
for T98G and H1299) and stained with crystal violet 10 to
21 days later.
DNA-Damaging Treatments
MCF7 (p53+ / + ) and H1299 (p53 / ) cells were UV-
irradiated at different dosages (J /m2) using a UV cross-
linker (Stratagene), or treated with adriamycin (doxorubicin;
Kyowa Hakko Kogyo, Tokyo, Japan) at different dosages.
Total RNA was isolated from the cells at selected times after
treatment and expression of Sema3B was examined by
Northern blotting.
Results
To identify additional p53 targets, we applied a cDNA
microarray to screen for p53- inducible transcripts [21].
We confirmed that this approach could detect the
elevated expressions of several well -known p53 target
genes (Table 1). Among dozens of genes that were
transactivated in a time-dependent manner after intro-
Table 1. Induction of Sema3B and Other p53 Target Genes in Ad -p53–
Infected U373MG Cells.
Gene UniGene Number Cy5 /Cy3*
p21 /WAF1 hs.179665 >15.0
FRACTALKINE hs.80420 10.4
GADD45A hs.80409 10.0
IGFBP3 hs.77326 9.7
SEMA3B hs.82222 7.8
p53DINP1 hs.75497 3.0
MDM2 hs.170027 2.4
cDNA microarray was performed with cells infected either with Ad -p53 or
Ad -LacZ.
*The mean ratio of Cy5 - labeled cDNA from Ad -p53– infected cells and Cy3 -
labeled cDNA from Ad -LacZ– infected cells.
Neoplasia . Vol. 4, No. 1, 2002
Semaphorin3B is a Target for p53 Ochi et al. 83
duction of exogeneous p53 to a p53-deficient cell line, we
confirmed significant induction of Sema3B (GenBank
NM004636) by a Northern blot analysis that identified its
major 3.4-kb transcript (Figure 1A ). To investigate
whether Sema3B was a direct target of p53, we searched
for one or more p53 binding sequences (p53BS) within
the gene and found a possible p53BS in its promoter
region (Figure 1B ), which revealed a 90% match to the
consensus p53 binding sequence [4] with a spacer of two
nucleotides (Figure 1C ).
To verify whether p53 was able to bind to oligonucleotides
corresponding to this candidate p53BS, we performed EMSA
(Figure 2A ) using nuclear extracts purified from H1299
(p53-null ) cells infected with Ad-p53. A shifted band was
Figure 1. Induction of Sema3B mRNA by exogenous p53 and detection of a potential p53 binding site in the promoter region. (A ) Northern blot analysis of Sema3B
and p21WAF1 mRNA. p53 -deficient U373MG cells were infected with Ad -p53 or Ad -LacZ at MOI of 80, and mRNA were isolated at the indicated times after
infection. Hybridization of the same blot with an actin probe served as a quantitative control for the amount of mRNA loaded in each lane. (B ) Nucleotide sequence of
the promoter region of the human Sema3B gene. A potential p53BS and putative TATA boxes are underlined. The locations of the primers used to amplify the native
promoter DNA are indicated by arrows. (C ) Comparison of sequences between the p53BS of the Sema3B gene and the p53 binding consensus sequence. R, purine;
Y, pyrimidine; W, A or T.
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observed after addition of the nuclear extract containing
wild- type p53, and was supershifted when anti–p53 anti-
body (Pab421) was added. This supershifted band was
supersupershifted when another anti–p53 antibody
(Pab1801) was added. Unlabeled self -oligonucleotides
(Self ), but not nonspecific oligonucleotides (TL), inhibited
the binding, indicating that p53 protein could in fact bind to
this p53BS in vitro.
To clarify the p53-dependent, transcription-enhancing
activity of this p53 binding sequence, we performed a
reporter assay with a luciferase gene that was fused to one
(p53BS1) or two copies (p53BS2) of the p53BS inserted
upstream of the SV40 promoter in a pGL3 promoter vector.
These constructs were cotransfected with a wild- type p53
(wt -p53 ) expression plasmid that strongly enhanced lucifer-
ase activity. No enhancement was seen when the reporter
plasmid was cotransfected with mutant p53 (mt-p53 [175]
or mt-p53 [277]; Figure 2B ). We also constructed a
luciferase vector containing an 880-bp DNA fragment
corresponding to the promoter region of the Sema3B gene
(Sema-pro880-wt) including the p53BS or the same DNA
fragment with a DNA substitution within the p53BS (Sema-
pro880-mt). Luciferase activity of Sema-pro880-wt, but not
Sema-pro880-mt, was enhanced by cotransfection of the
plasmid designed to express wt-p53. This enhancement
was not observed after cotransfection with plasmids
designed to express mt-p53. The reporter gene assay,
combined with the result of EMSA, clearly indicated that
Sema3B is a bonafide target of wild - type p53.
We then examined transcriptional activation of Sema3B
by endogenous p53 in response to cellular stresses causing
DNA damage (UV irradiation and adriamycin treatment ),
using MCF7 (p53+ / + ) and H1299 (p53 / ) cells. As
shown in Figure 3, expression of Sema3B mRNA increased
remarkably in MCF7 cells after exposure to either genotoxic
stress, in a time-dependent manner. However, expression
was unchanged in H1299 cells (data not shown). We noted
that induction of p21WAF1 in response to these treatments
reached a maximum 12 and 24 hours after treatment,
whereas expression of Sema3B mRNA increased up to
72 hours after the exposure. We had previously observed the
same induction pattern of p53AIP1 mRNA after these
exposures; this similarity implies that modification of p53
protein is required for induction of Sema3B.
We performed colony formation assays to investigate the
effect of Sema3B on cell growth, using expression vectors
(sense-Sema3B -FLAG or sense-Sema3B ) designed to
express Sema3B protein with or without a FLAG tag at the
Figure 2. Sema3B as a direct target of p53. (A ) EMSA, using purified nuclear
extracts from H1299 (p53 /  ) cells infected with Ad -p53. The probe was a
32P - labeled oligonucleotide designed according to the p53BS sequence
present in the gene’s promoter. Interaction between p53 protein and DNA was
inhibited by unlabeled oligonucleotides corresponding to the binding site of the
Sema3B gene (Self ) but not by nonspecific oligonucleotides (TL ). (B )
Reporter assay. Vectors containing either one (p53BS1 ) or two (p53BS2 )
copies of the p53 binding site, or an 880 -bp genomic sequence in the
promoter encompassing the p53BS (Sema -prom. ) and their mutants
( p53BS1.mt., p53BS2.mt., and Sema -prom.mt. ) were constructed.
These vectors were cotransfected into H1299 cells with wild - type p53 (wt -
p53 ) expression vector, mutant p53 (mt - p53[ 175 ] or mt - p53[ 277 ] )
expression vector, or mock vector (p53(  ) ). Luciferase activity is indicated
relative to the activity of either pGL3 promoter or pGL3 basic vector.
Figure 3. Induction of Sema3B and p21WAF1 mRNA in MCF7 (p53+ / + ) cells
in response to genotoxic stresses, shown by Northern blot analysis. mRNA
were isolated at the indicated times after treatment with adriamycin or UV
radiation. Expression of the actin gene served as a quantity control.
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C-terminal. As a negative control, we also prepared an
expression vector in which the entire coding region of
Sema3B was inserted in the antisense direction (anti-
sense-Sema3B ). Each of these vectors was transfected
into T98G (glioblastoma), U373MG (glioblastoma), or
H1299 ( lung cancer) cells, all of which lack wild - type p53.
Expression of Sema3B protein after transfection with sense-
Sema3B -FLAG vector was confirmed by immunoblotting,
using mouse anti–FLAG monoclonal antibody (Kodak; data
not shown). After 2 weeks of incubation in geneticin-
containing media, ectopic expression of Sema3B had
reduced the numbers of colonies in all three cell lines
(Figure 4; data for U373MG not shown). Similar results were
obtained when we used sense-Sema3B -FLAG expression
vector (data not shown), suggesting that Sema3Bmight play
a role in either apoptosis or cell cycle arrest.
Discussion
In addition to the specific functions of semaphorins in axon
guidance and axonal repulsion, emerging evidence indicates
their involvement in neuronal apoptosis [22]. Semaphorin3A
(Sema3A), a member of the same class as Sema3B,
induces neuronal apoptosis by binding to its receptor,
neurophilin -1 (NRP1), which is known as a receptor for
Sema3B [23,24]. On the other hand, VEGF165 (vascular
endothelial growth factor ) can block Sema3A-NRP1 signal-
ing for neuronal apoptosis by directly competing with
Sema3A for binding to NRP1 [23,24]. Therefore, the balance
between Sema3A and VEGF165 might determine a cell’s
fate, survival, or apoptosis. We speculate that Sema3B is
also involved in regulating apoptosis via binding to NRP1, by
cooperating with Sema3A or competing with VEGF165.
Several groups have reported a possible role of p53 in
neuronal apoptosis; for one thing, expression of p53 mRNA
precedes neuronal apoptosis in neurons of injured brain and
spinal cord [25]. Second, neuronal cells from p53 /
knockout mice are resistant to apoptosis induced by neuro-
nal injury, both in vitro and in vivo [26]. As a third line of
evidence, experimental overexpression of p53 in neuronal
cells can induce apoptosis [26,27]. These data indicate that
p53 plays an important role in regulating neuronal apoptosis,
probably through the transcriptional regulation of target
gene(s). Indeed, in our experiments, overexpression of
Sema3B suppressed the growth of neuronal and non-
neuronal cancer cells. Taken together, the results support
a notion that Sema3Bmight be one of the mediators involved
in p53-dependent apoptosis for not only neuronal cells but
also non-neuronal ones. The information presented here
should shed light toward a fuller understanding of the
physiological functions of p53.
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